Interleukin Genetics launches new version of Heart Health Test
This article was originally published in Clinica
Executive Summary
Interleukin Genetics has launched its enhanced Heart Health Genetic Test in the US and Canada. It is an upgrade of the Gensona Heart Health Genetic Test, marketed by Quixtar/Amway, which was launched in 2006. Interleukin developed the diagnostic and licensed it to Quixtar, which prepares the test kit. Interleukin analyses the test and provides its report via its CLIA-registered laboratory. The Waltham, Massachusetts firm explained that the test itself was not new, but it now provides a comprehensive report, which includes quantified risk information on heart attack and coronary artery disease, and more complete information on a person's inflammation-based genetic risk factor for heart attack.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.